electroCore (ECOR)


Market Price (11/20/2026): $4.83 | Market Cap: $44.6 MilSector: Health Care | Industry: Life Sciences Tools & Services

electroCore (ECOR)


Market Price (11/20/2026): $4.83
Market Cap: $44.6 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -42%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Targeted Therapies, and Remote Patient Monitoring.

Weak multi-year price returns
2Y Excs Rtn is -89%, 3Y Excs Rtn is -81%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -29%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31%

Key risks
ECOR key risks include [1] its persistent cash burn and need for additional financing, Show more.

0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -42%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Targeted Therapies, and Remote Patient Monitoring.
2 Weak multi-year price returns
2Y Excs Rtn is -89%, 3Y Excs Rtn is -81%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33%
4 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -29%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31%
6 Key risks
ECOR key risks include [1] its persistent cash burn and need for additional financing, Show more.

ECOR in ETFs

Weight = ECOR's share of each fund

VTI0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/19/2026

Nov 19: down 6.2% in one day (S&P 500 down 2.0%)
The stock fell without specific company news, occurring amidst a broader market decline. This downturn was characterized by troubling signals about the economy and a general market wipeout.

Down 61.0% from its Sep 22 high to Nov 17 (S&P 500 down 5.3%)
The stock declined significantly over this period without specific company news driving the overall trend. This trend, which saw no company headlines on its biggest down days like October 13 and November 6, was not driven by its November 4 earnings report.

Nov 5: up 4.8% the day after its Nov 4 earnings report (S&P 500 down 4.4%)
The stock climbed following its Q3 2026 earnings report, which revealed a significantly reduced net loss and improved diluted EPS. This happened despite missing revenue estimates and a sharp decline in the S&P 500.

Show more
Prices as of 11/19/2026

Nov 19: down 6.2% in one day (S&P 500 down 2.0%)
The stock fell without specific company news, occurring amidst a broader market decline. This downturn was characterized by troubling signals about the economy and a general market wipeout.

Down 61.0% from its Sep 22 high to Nov 17 (S&P 500 down 5.3%)
The stock declined significantly over this period without specific company news driving the overall trend. This trend, which saw no company headlines on its biggest down days like October 13 and November 6, was not driven by its November 4 earnings report.

Nov 5: up 4.8% the day after its Nov 4 earnings report (S&P 500 down 4.4%)
The stock climbed following its Q3 2026 earnings report, which revealed a significantly reduced net loss and improved diluted EPS. This happened despite missing revenue estimates and a sharp decline in the S&P 500.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -20.3% change in ECOR stock from 7/31/2026 to 11/19/2026 was primarily driven by a -18.5% change in the company's P/S Multiple.
(LTM values as of)731202611192026Change
Stock Price ($)6.084.85-20.3%
Change Contribution By: 
Total Revenues ($ Mil)35388.8%
P/S Multiple1.61.3-18.5%
Shares Outstanding (Mil)910-10.1%
Cumulative Contribution-20.3%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/19/2026
ReturnCorrelation
ECOR-20.3% 
Market (SPY)-3.9%22.5%
Sector (XLV)9.6%25.8%

Fundamental Drivers

The -25.5% change in ECOR stock from 4/30/2026 to 11/19/2026 was primarily driven by a -29.5% change in the company's P/S Multiple.
(LTM values as of)430202611192026Change
Stock Price ($)6.514.85-25.5%
Change Contribution By: 
Total Revenues ($ Mil)323818.5%
P/S Multiple1.81.3-29.5%
Shares Outstanding (Mil)910-10.8%
Cumulative Contribution-25.5%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/19/2026
ReturnCorrelation
ECOR-25.5% 
Market (SPY)0.1%19.3%
Sector (XLV)22.6%15.6%

Fundamental Drivers

The -3.8% change in ECOR stock from 10/31/2025 to 11/19/2026 was primarily driven by a -16.5% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511192026Change
Stock Price ($)5.044.85-3.8%
Change Contribution By: 
Total Revenues ($ Mil)283837.1%
P/S Multiple1.51.3-16.0%
Shares Outstanding (Mil)810-16.5%
Cumulative Contribution-3.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/19/2026
ReturnCorrelation
ECOR-3.8% 
Market (SPY)6.1%24.5%
Sector (XLV)25.1%17.4%

Fundamental Drivers

The -20.8% change in ECOR stock from 10/31/2023 to 11/19/2026 was primarily driven by a -52.5% change in the company's P/S Multiple.
(LTM values as of)1031202311192026Change
Stock Price ($)6.124.85-20.8%
Change Contribution By: 
Total Revenues ($ Mil)1138249.4%
P/S Multiple2.71.3-52.5%
Shares Outstanding (Mil)510-52.3%
Cumulative Contribution-20.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/19/2026
ReturnCorrelation
ECOR-20.8% 
Market (SPY)77.5%20.5%
Sector (XLV)49.8%17.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ECOR Return-63%-56%55%172%-72%8%-79%
Peers Return-2%9%-28%-21%-11%0%-46%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
ECOR Win Rate17%42%67%58%50%55% 
Peers Win Rate47%50%39%47%33%48% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
ECOR Max Drawdown-81%-76%-48%-29%-78%-61% 
Peers Max Drawdown-44%-49%-59%-57%-59%-47% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: LIVN, STIM, INSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/19/2026 (YTD)

How Low Can It Go

EventECORS&P 500
2024 Yen Carry Trade Unwind
  % Loss-10.2%-7.8%
  % Gain to Breakeven11.4%8.5%
  Time to Breakeven42 days18 days
2023 SVB Regional Banking Crisis
  % Loss-40.3%-6.7%
  % Gain to Breakeven67.4%7.1%
  Time to Breakeven23 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-57.5%-24.5%
  % Gain to Breakeven135.2%32.4%
  Time to Breakeven724 days427 days
2020 COVID-19 Crash
  % Loss-70.9%-33.7%
  % Gain to Breakeven244.1%50.9%
  Time to Breakeven12 days140 days

Compare to LIVN, STIM, INSP

In The Past

electroCore's stock fell -10.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 11.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventECORS&P 500
2023 SVB Regional Banking Crisis
  % Loss-40.3%-6.7%
  % Gain to Breakeven67.4%7.1%
  Time to Breakeven23 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-57.5%-24.5%
  % Gain to Breakeven135.2%32.4%
  Time to Breakeven724 days427 days
2020 COVID-19 Crash
  % Loss-70.9%-33.7%
  % Gain to Breakeven244.1%50.9%
  Time to Breakeven12 days140 days

Compare to LIVN, STIM, INSP

In The Past

electroCore's stock fell -10.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 11.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About electroCore (ECOR)

electroCore, Inc. (ECOR) is a commercial-stage medical device company focused on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. The company's innovative approach centers on providing a drug-free option for pain management by delivering electrical impulses to the vagus nerve.

Its lead product is gammaCore Sapphire, a prescription-only, rechargeable, and reloadable handheld device designed for regular or intermittent use over many years. This nVNS therapy is specifically intended for the acute treatment of pain associated with migraine and episodic cluster headaches in adult patients, serving individuals who are prescribed the device by their healthcare providers.

AI Analysis | Feedback

Here are 1-3 brief analogies for electroCore (ECOR):

  • ResMed for migraine and cluster headache devices.
  • Medtronic for non-invasive headache treatments.

AI Analysis | Feedback

  • gammaCore: A prescription-only non-invasive vagus nerve stimulation (nVNS) therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
  • gammaCore Sapphire: A rechargeable and reloadable handheld device that delivers the gammaCore nVNS therapy.

AI Analysis | Feedback

Major Customers of electroCore (ECOR)

electroCore, Inc. primarily sells its prescription-only non-invasive vagus nerve stimulation (nVNS) therapies, such as gammaCore Sapphire, to individuals through healthcare providers and pharmacies. The ultimate customers are patients who have received a prescription for the device.

Categories of Individual Customers:

  • Individuals suffering from migraine, for the acute treatment of associated pain.
  • Individuals suffering from episodic cluster headache, for the acute treatment of associated pain.

AI Analysis | Feedback

  • Benchmark Electronics, Inc. (BHE)
  • Zynex Medical, Inc. (ZYXI)

AI Analysis | Feedback

Daniel S. Goldberger, Chief Executive Officer

Daniel S. Goldberger has over 35 years of leadership and medical device experience. Prior to joining electroCore, he served as Executive Chairman, Chairman, and interim Chief Executive Officer of Repro Med Systems, Inc. (RMS). He also held positions as Director and Chief Executive Officer of Xtant Medical Holdings, Inc. and Director and Chief Executive Officer of Sound Surgical Technologies. Earlier in his career, he held various positions at Glucon, Inc., OSI Systems, Ohmeda, Nellcor, and Hewlett Packard. Goldberger is recognized for his expertise in turnarounds, commercial execution, capital formation, and product development across diverse medical technology companies.

Joshua Lev, Chief Financial Officer

Joshua Lev was appointed Chief Financial Officer of electroCore, effective October 4, 2024. He previously served as Chief Strategy Officer for the company since January 2022, and as VP of Business Development, Strategy, and Financial Planning since February 2020. Before joining electroCore, Mr. Lev accumulated over 15 years of experience in the financial services industry as an investment banker and investor, focusing on emerging growth companies. He was a co-founder of Aracle Capital, LLC from March 2014 through February 2020, and served as Director of Business Development at Wellfleet Partners, Inc. from 2011 to February 2020, where he focused on capital raising, M&A, and strategic transactions.

Peter S. Staats, MD, MBA, Chief Medical Officer

Dr. Peter Staats is a co-founder of electroCore and is responsible for overseeing the clinical development of gammaCoreTM. He previously served on the company's board of directors. Dr. Staats is internationally recognized for his work in neuromodulation strategies and minimally invasive procedures for chronic pain, and he founded the Division of Pain Medicine at Johns Hopkins University, where he served as director for 10 years.

Manny Marques, Senior Vice President, Operations

Manny Marques serves as the Senior Vice President of Operations for electroCore.

Mitch DeShon, Vice President Global Sales & Business Development

Mitch DeShon has over 20 years of experience in the medical device industry. He has held executive sales and business development roles at companies such as Sound Surgical, ICN Pharmaceuticals, ESC/Lumenis, and Sherwood Medical. Prior to electroCore, he was the Vice President of Sales for Venus Concept, managing the Australia/APAC region.

AI Analysis | Feedback

Here are the key risks to electroCore's business:

  1. Dependence on Additional Funding and Path to Profitability: electroCore is currently unprofitable and continues to incur net losses, requiring the company to raise additional capital to fund its ongoing operations, product development, and commercialization strategies. Despite some revenue growth, the company's widening net loss and negative operating cash flow indicate a persistent cash burn that necessitates significant revenue increases to achieve cash flow positivity and long-term financial stability.

  2. High Customer Concentration and Reliance on the VA Channel: A substantial portion of electroCore's revenue, particularly within its prescription device segment, is generated through the U.S. Department of Veterans Affairs (VA) channel. For instance, the VA channel accounted for approximately 70% of total revenue in Q2 2025 and 70.6% in 2024. This heavy dependence on a single customer channel exposes the company to significant risk, as any adverse changes in VA procurement policies, reimbursement rates, or budget allocations could severely destabilize its financial model.

  3. Reimbursement Challenges and Market Adoption: While electroCore's products, such as gammaCore, have received regulatory clearances, the company faces ongoing hurdles in securing widespread and adequate reimbursement from both governmental payers (like the Centers for Medicare and Medicaid Services, CMS) and private insurance providers. Decisions from entities like CMS have historically rejected appeals for higher payment amounts, limiting the commercial viability of its novel medical devices. Slow market penetration and challenges in establishing broad reimbursement can hinder patient access and overall revenue growth for its non-invasive vagus nerve stimulation (nVNS) therapies.

AI Analysis | Feedback

null

AI Analysis | Feedback

electroCore, Inc. (ECOR) develops and commercializes gammaCore, a non-invasive vagus nerve stimulation (nVNS) therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults, and for the preventive treatment of cluster headache and migraine in adults.

The addressable markets for electroCore's main products and services are as follows:

Migraine Market

  • Global Market: The global migraine drugs market was valued at approximately USD 10.88 billion across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) in 2023 and is projected to increase through 2034. Other estimates for the global migraine drugs market include a valuation of USD 6.81 billion in 2024, projected to reach USD 13.34 billion by 2030, growing at a CAGR of 10.9%. Another source valued the global market at USD 7.67 billion in 2025, projected to grow to USD 19.71 billion by 2034, exhibiting a CAGR of 11.06%.
  • U.S. Market: The U.S. migraine market accounted for approximately USD 6.79 billion in 2023, making it the highest among the 7MM. The U.S. migraine drugs market generated a revenue of USD 2.937 billion in 2024 and is expected to reach USD 6.1712 billion by 2030, growing at a CAGR of 13.2% from 2025 to 2030.

Cluster Headache Market

  • Global Market: The global cluster headache market was valued at approximately USD 456.6 million in 2024 and is projected to reach USD 899.8 million by 2035, expanding at a CAGR of 6.4% from 2025 to 2035. Another report estimated the global market to be valued at USD 449.3 million in 2025 and expected to reach USD 694.0 million by 2032, exhibiting a CAGR of 6.4%.
  • U.S. Market: The total cluster headache treatment market size across the 7MM (US, EU4, UK, and Japan) was around USD 890 million in 2023. The U.S. captured the highest share of this market, approximately USD 467 million in 2023. North America, specifically, held a dominant market share of 41.7% in the global cluster headache market in 2025, with the U.S. being a significant contributor due to its developed healthcare infrastructure.

AI Analysis | Feedback

electroCore (ECOR) is anticipated to drive future revenue growth over the next two to three years through several key initiatives:

  • Expansion within the U.S. Prescription Channel, particularly the VA Hospital System: The company has seen continued growth in prescription device sales for both gammaCore and the newly acquired Quell Fibromyalgia product within the Department of Veteran Affairs (VA) hospital system. Management is strategically investing in strengthening the VA and managed-care channels to further accelerate this growth.
  • Growth of the Truvaga Wellness Product Line and AI-Enabled Software Strategy: Truvaga wellness sales have demonstrated significant year-over-year increases, with the company actively increasing its media budget to drive further growth in this direct-to-consumer channel. Additionally, electroCore is developing a next-generation AI-enabled app for Truvaga to foster recurring revenue.
  • Synergy and Expansion from the NeuroMetrix (Quell) Acquisition: The acquisition of NeuroMetrix, including the Quell Fibromyalgia product, is already exceeding expectations and contributing to revenue, particularly within the VA channel. electroCore also plans to launch additional health and wellness offerings, such as Quell Relief for lower extremity pain, leveraging this acquisition.
  • International Market Expansion and Reimbursement Gains: electroCore is pursuing commercialization in new international markets, including a planned royalty arrangement for China. The company has also secured long-term reimbursement approval for gammaCore in Belgium and has plans for expansion into Canada and the UK, broadening its global footprint.
  • Development of New Use Cases and Target Demographics for nVNS Products: The company expects to introduce new applications and target populations for its non-invasive vagus nerve stimulation (nVNS) products. This includes exploring adjunctive treatment for symptoms associated with Post-Traumatic Stress Disorder (PTSD) using gammaCore Sapphire.

AI Analysis | Feedback

Share Issuance

  • In June 2024, electroCore closed a registered direct offering and concurrent private placements, generating approximately $9.3 million in gross proceeds. These funds were intended for sales and marketing, working capital, and general corporate purposes.
  • Approximately $5.645 million of the gross proceeds from the June 2024 offering were provided by directors and officers of electroCore.
  • In October 2025, electroCore issued 360,737 shares in a private placement, valued at approximately $1.856 million, to satisfy outstanding legal fee obligations, with no cash proceeds received by the company.

Inbound Investments

  • Directors and officers of electroCore provided approximately $5.645 million as part of the $9.3 million gross proceeds raised in a June 2024 offering.
  • In October 2025, electroCore issued 106,351 private placement shares to "Avenue" in connection with a loan agreement.

Outbound Investments

  • In the third quarter of 2025, electroCore completed a strategic acquisition of NeuroMetrix, which brought the Quell portfolio of products, including Quell Fibromyalgia.

Capital Expenditures

  • Specific dollar values for traditional capital expenditures over the last 3-5 years are not readily available in the provided information.
  • The company has focused on targeted investments in sales and marketing to support commercial efforts, as noted in Q2 and Q3 2025.
  • Increased development costs associated with a next-generation mobile application were reported in the third quarter of 2025, indicating investment in research and development.

Better Bets vs. electroCore (ECOR)

Peer Outperformance in Life Sciences Tools & Services

ECOR has outperformed 62% of its 109 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it is NTRA. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that ECOR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
61%
of 125 industry peers · -0.6% return
3Y
53%
of 115 industry peers · -20.6% return
5Y
62%
of 109 industry peers · -57.3% return
Life Sciences Tools & Services peers with revenue growth within 4pp of ECOR's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
ECOR electroCore 43.1% -3.8x -0.6%-20.6%-57.3% —
NTRA Natera 43.5% -253.6x 32.8%429.1%181.0% +238pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is ECOR's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.1%78.5%200.4% CAH 522% · MCK 393% · COR 200%
Health Care Services 20 29.8%19.4%13.7% RDNT 146% · HIMS 119% · DGX 92%
Managed Health Care 8 54.9%-10.9%-9.1% OSCR 154% · HQY 59% · ELV 1%
Health Care Facilities 26 14.5%11.8%-10.2% THC 240% · NHC 208% · EHC 184%
Health Care Equipment 50 -1.7%2.7%-17.2% GKOS 395% · UFPT 330% · TMDX 313%
Health Care Supplies 11 22.8%-2.2%-40.4% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals 60 -15.9%-1.5%-42.0% LQDA 1229% · KNSA 667% · XERS 632%
Life Sciences Tools & Services ← 110 -21.8%-26.1%-74.7% AXGN 477% · NTRA 181% · MEDP 179%
Biotechnology 370 -35.1%-42.2%-84.4% ELVN 1306% · TRVI 1194% · DNTH 1168%
Health Care Technology 23 -20.5%-61.1%-88.1% VEEV -14% · DOCS -52%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ECORLIVNSTIMINSPMedian
NameelectroC.LivaNova Neuronet.Inspire . 
Mkt Price4.8392.071.2456.2530.54
Mkt Cap0.05.10.11.60.9
Rev LTM381,507160881520
Op Inc LTM-13162-15162
FCF LTM-11129-109844
FCF 3Y Avg-9143-217835
CFO LTM-11238-813563
CFO 3Y Avg-9216-1911653

Growth & Margins

ECORLIVNSTIMINSPMedian
NameelectroC.LivaNova Neuronet.Inspire . 
Rev Chg LTM27.3%11.7%23.0%-0.2%17.4%
Rev Chg 3Y Avg43.1%10.5%35.6%16.4%26.0%
Rev Chg Q11.5%9.9%12.5%-7.9%10.7%
QoQ Delta Rev Chg LTM2.7%2.4%3.0%-2.0%2.6%
Op Inc Chg LTM5.3%-16.4%60.4%-57.1%-5.6%
Op Inc Chg 3Y Avg14.0%90.3%13.8%80.7%47.3%
Op Mgn LTM-33.1%10.7%-9.4%1.8%-3.8%
Op Mgn 3Y Avg-44.5%10.9%-25.5%2.6%-11.4%
QoQ Delta Op Mgn LTM4.5%-2.0%5.4%-4.2%1.2%
CFO/Rev LTM-28.7%15.8%-5.2%15.3%5.1%
CFO/Rev 3Y Avg-31.0%15.7%-18.7%13.6%-2.5%
FCF/Rev LTM-28.7%8.6%-6.0%11.1%1.3%
FCF/Rev 3Y Avg-31.1%10.5%-20.2%9.1%-5.5%

Valuation

ECORLIVNSTIMINSPMedian
NameelectroC.LivaNova Neuronet.Inspire . 
Mkt Cap0.05.10.11.60.9
P/S1.33.40.61.81.6
P/Op Inc-3.831.3-6.4103.213.7
P/EBIT-4.133.4-6.353.114.6
P/E-3.825.9-4.116.26.2
P/CFO-4.421.3-11.512.13.8
Total Yield-26.3%3.9%-24.2%6.2%-10.2%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-14.8%4.5%-40.0%3.3%-5.7%
D/E0.20.10.90.00.1
Net D/E0.0-0.00.7-0.20.0

Returns

ECORLIVNSTIMINSPMedian
NameelectroC.LivaNova Neuronet.Inspire . 
1M Rtn-35.5%15.5%-37.4%-21.2%-28.3%
3M Rtn-52.7%17.7%-59.9%-8.2%-30.4%
6M Rtn-19.4%25.0%4.2%25.7%14.6%
12M Rtn-1.0%70.8%-16.8%-32.6%-8.9%
3Y Rtn-20.9%96.5%-8.1%-60.7%-14.5%
1M Excs Rtn-29.9%21.8%-33.9%-16.5%-23.2%
3M Excs Rtn-50.7%20.3%-55.3%-6.4%-28.6%
6M Excs Rtn-19.0%25.4%4.6%26.1%15.0%
12M Excs Rtn-16.4%58.8%-29.1%-44.8%-22.8%
3Y Excs Rtn-81.2%22.0%-74.5%-122.7%-77.8%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Bioelectronic Innovations32251695
Total32251695


Operating Income by Segment
$ Mil202520242023
Bioelectronic Innovations-13-12-19
Total-13-12-19


Net Income by Segment
$ Mil20242023
Bioelectronic Innovations-12-19
Total-12-19


Price Behavior

Price Behavior
Market Price$4.85 
Market Cap ($ Bil)0.0 
First Trading Date06/22/2018 
Distance from 52W High-60.5% 
   50 Days200 Days
DMA Price$8.67$7.71
DMA Trenddownup
Distance from DMA-44.0%-37.1%
 3M1YR
Volatility103.6%95.0%
Downside Capture393.22307.00
Upside Capture50.10264.68
Correlation (S&P 500)17.9%25.7%
ECOR Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.772.422.501.681.891.11
Up Beta3.802.65-0.37-0.500.270.53
Down Beta-0.362.353.851.391.361.14
Up Capture99%177%403%315%638%280%
Bmk +ve Days12182862130427
Stock +ve Days6163163123365
Down Capture523%286%201%187%162%110%
Bmk -ve Days10253664121325
Stock -ve Days16263261124372

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ECOR
ECOR-4.0%95.0%0.39-
Sector ETF (XLV)18.3%17.1%0.8018.1%
Equity (SPY)9.7%13.9%0.4125.6%
Gold (GLD)-10.5%29.0%-0.3921.1%
Commodities (DBC)28.2%21.5%1.05-2.7%
Real Estate (VNQ)8.8%14.3%0.3416.7%
Bitcoin (BTCUSD)-32.3%43.7%-0.7823.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ECOR
ECOR-21.2%91.9%0.15-
Sector ETF (XLV)7.7%15.4%0.3011.1%
Equity (SPY)10.5%17.3%0.4416.4%
Gold (GLD)14.0%19.2%0.588.6%
Commodities (DBC)6.8%19.6%0.233.0%
Real Estate (VNQ)0.7%19.0%-0.0714.4%
Bitcoin (BTCUSD)-0.6%51.4%0.179.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ECOR
ECOR-34.6%127.5%0.08-
Sector ETF (XLV)11.5%16.8%0.5617.6%
Equity (SPY)14.5%18.0%0.6818.1%
Gold (GLD)10.7%16.6%0.525.5%
Commodities (DBC)7.2%18.2%0.316.2%
Real Estate (VNQ)5.8%20.7%0.2313.6%
Bitcoin (BTCUSD)56.3%66.3%0.966.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.4 Mil
Short Interest: % Change Since 101520263.3%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest5.2 days
Basic Shares Quantity10.0 Mil
Short % of Basic Shares3.6%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20264.8%-8.2% 
8/6/202620.7%48.4%37.5%
5/6/2026-5.9%-5.1%30.9%
3/19/2026-4.7%-8.2%-3.7%
1/20/202610.2%14.5%-10.3%
11/5/202523.2%27.8%3.4%
8/6/2025-29.1%-25.8%-29.4%
5/7/2025-23.8%-32.4%-15.9%
...
SUMMARY STATS   
# Positive131415
# Negative181715
Median Positive4.8%6.9%14.6%
Median Negative-5.5%-9.4%-15.9%
Max Positive23.2%48.4%67.5%
Max Negative-29.1%-38.4%-57.5%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20264.8%-8.2% 
8/6/202620.7%48.4%37.5%
5/6/2026-5.9%-5.1%30.9%
3/19/2026-4.7%-8.2%-3.7%
1/20/202610.2%14.5%-10.3%
11/5/202523.2%27.8%3.4%
8/6/2025-29.1%-25.8%-29.4%
5/7/2025-23.8%-32.4%-15.9%
3/12/2025-26.5%-38.4%-57.5%
1/17/20251.3%8.3%14.6%
11/13/20241.5%-25.8%1.6%
8/7/2024-1.3%-2.1%-2.6%
5/8/2024-5.4%2.2%-9.5%
3/13/2024-5.6%-1.2%-11.0%
1/16/20245.0%17.2%15.6%
11/8/20232.8%8.0%-3.8%
8/9/2023-8.8%-12.2%4.8%
5/3/2023-5.0%-4.6%-20.2%
3/8/20239.5%-4.5%53.4%
1/17/2023-8.0%5.7%-29.5%
11/3/2022-23.8%-22.3%10.0%
8/4/2022-7.5%4.6%-21.2%
5/5/2022-3.2%-34.0%41.9%
3/15/20222.8%22.4%1.8%
1/18/20228.3%-14.4%-25.8%
11/4/2021-5.0%-9.4%-34.5%
8/5/20214.3%2.3%3.3%
5/6/2021-2.0%2.0%17.0%
3/11/20210.0%4.2%-14.5%
1/11/2021-3.6%4.7%67.5%
11/12/2020-1.2%-7.2%8.4%
SUMMARY STATS   
# Positive131415
# Negative181715
Median Positive4.8%6.9%14.6%
Median Negative-5.5%-9.4%-15.9%
Max Positive23.2%48.4%67.5%
Max Negative-29.1%-38.4%-57.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/06/202610-Q
03/31/202605/06/202610-Q
12/31/202503/19/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202403/12/202510-K
09/30/202411/13/202410-Q
06/30/202408/07/202410-Q
03/31/202405/08/202410-Q
12/31/202303/13/202410-K
09/30/202311/08/202310-Q
06/30/202308/09/202310-Q
03/31/202305/03/202310-Q
12/31/202203/08/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/06/202610-Q
03/31/202605/06/202610-Q
12/31/202503/19/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202403/12/202510-K
09/30/202411/13/202410-Q
06/30/202408/07/202410-Q
03/31/202405/08/202410-Q
12/31/202303/13/202410-K
09/30/202311/08/202310-Q
06/30/202308/09/202310-Q
03/31/202305/03/202310-Q
12/31/202203/08/202310-K
09/30/202211/03/202210-Q
06/30/202208/04/202210-Q
03/31/202205/05/202210-Q
12/31/202103/10/202210-K
09/30/202111/04/202110-Q
06/30/202108/05/202110-Q
03/31/202105/06/202110-Q
12/31/202003/11/202110-K
09/30/202011/12/202010-Q
06/30/202008/13/202010-Q
03/31/202005/15/202010-Q
12/31/201903/30/202010-K

Recent Forward Guidance

Updated 11/5/2026

Latest: Q3 2026 Earnings Reported 11/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported39.00 Mil40.50 Mil42.00 Mil   
2027 Revenue GrowthReported30.0%35.0%40.0% 5.0%Higher NewGuidance: 30.0% for 2026


Prior: Q2 2026 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q3 2027 Adjusted EBITDAReported 0    
2026 General and Administrative ExpenseReported -0.03    
2026 Revenue GrowthReported 30.0%  0.0%RaisedGuidance: 30.0% for 2026
2027 Incentive Compensation Variable ExpenseReported 0.27  -8.0%LoweredGuidance: 0.35 for 2027
2027 Sales and Marketing ExpenseReported 0.54    

Q1 2026 Earnings Reported 5/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Revenue GrowthReported 30.0%  0.0%AffirmedGuidance: 30.0% for 2026

Insider Activity

Updated 11/19/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Fox, MichaelSee RemarksDirectBuy111920265.252,50013,116695,148Form
2Errico, Thomas JDirectBuy111620265.4410,00054,4002,034,038Form
3Errico, Thomas JDirectBuy92220269.825,00049,0823,572,191Form
4Lev, Joshua SCFO and Interim PresidentDirectSell82520269.363,00028,080794,561Form
5Lev, Joshua SCFO and Interim PresidentDirectSell82520269.885,00049,400838,703Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Fox, MichaelSee RemarksDirectBuy111920265.252,50013,116695,148Form
2Errico, Thomas JDirectBuy111620265.4410,00054,4002,034,038Form
3Errico, Thomas JDirectBuy92220269.825,00049,0823,572,191Form
4Lev, Joshua SCFO and Interim PresidentDirectSell82520269.363,00028,080794,561Form
5Lev, Joshua SCFO and Interim PresidentDirectSell82520269.885,00049,400838,703Form
6Lev, Joshua SCFO and Interim PresidentDirectSell825202610.2212,000122,640867,566Form
7Errico, Thomas JDirectBuy81720269.855,00049,2723,383,331Form
8Goldberger, Daniel S DirectSell61220266.8080,000544,0001,438,003Form
9Lev, Joshua SCFO and Interim PresidentDirectSell52920269.006,66760,003764,001Form
10Errico, Thomas JDirectBuy52620265.999,99259,8522,156,825Form
11Lev, Joshua SCFO and Interim PresidentDirectSell52220266.503,00019,500595,114Form
12Goldberger, Daniel SDirectSell41420266.0216,07296,7531,754,655Form
13Lev, Joshua SChief Financial OfficerDirectSell120520255.052,50012,625109,418Form
14Goldberger, Daniel SChief Executive OfficerDirectBuy120320254.841,0004,8401,416,015Form
15Lev, Joshua SChief Financial OfficerDirectSell111420256.182,16613,386146,262Form
Core Cache Last Updated: 11/19/2026